Patents Assigned to Genzyme Corporation
  • Patent number: 10604518
    Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: March 31, 2020
    Assignee: GENZYME CORPORATION
    Inventors: Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
  • Publication number: 20200080063
    Abstract: Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods.
    Type: Application
    Filed: August 28, 2019
    Publication date: March 12, 2020
    Applicant: Genzyme Corporation
    Inventors: Jianguo Yang, Yang Yang
  • Patent number: 10583154
    Abstract: The present invention relates to non-mercurial preservatives, including antimicrobial polyamide polymers and octenidine, and to methods of use thereof to produce preservative-containing multi-dose formulations. The preservative-containing multi-dose formulations exhibit resistance to one or more contaminating microorganisms, and have advantageous properties with respect to long term stability of biological and small molecule active ingredients.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: March 10, 2020
    Assignees: Boehringer Ingelheim Animal Health USA Inc., GENZYME CORPORATION
    Inventors: Guillaume Rigaut, Celine Loss-Dunod, Alexis Guy Andre Lucien Parisot, Pradeep K. Dhal
  • Publication number: 20200069822
    Abstract: Provided herein are methods of reducing bioburden of a chromatography resin that include exposing a container including a composition including (i) a chromatography resin and (ii) a liquid including at least on alcohol to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one alcohol are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation. Also provided are reduced bioburden chromatography columns including the reduced bioburden chromatography resin, compositions including a chromatography resin and a liquid including at least one alcohol, methods of performing reduced bioburden column chromatography using one of these reduced bioburden chromatography columns, and integrated, closed, and continuous processes for reduced bioburden manufacturing of a purified recombinant protein.
    Type: Application
    Filed: August 16, 2019
    Publication date: March 5, 2020
    Applicant: Genzyme Corporation
    Inventors: Rohan Patil, Chad Varner
  • Patent number: 10577583
    Abstract: Provided herein are methods of perfusion culturing an adherent mammalian cell using a shake flask and a plurality of microcarriers, and various methods that utilize these culturing methods.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: March 3, 2020
    Assignee: Genzyme Corporation
    Inventors: Jianguo Yang, Yang Yang, Jennifer Tengtrakool, Weichang Zhou
  • Patent number: 10570367
    Abstract: Provided herein are seed train processes and methods of producing a recombinant protein that include the use of these seed train processes.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: February 25, 2020
    Assignee: Genzyme Corporation
    Inventors: Michael Bruninghaus, Konstantin Konstantinov, Benjamin Wright, Weichang Zhou
  • Publication number: 20200040091
    Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
    Type: Application
    Filed: April 10, 2019
    Publication date: February 6, 2020
    Applicant: GENZYME CORPORATION
    Inventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
  • Publication number: 20190389943
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: July 1, 2019
    Publication date: December 26, 2019
    Applicants: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 10508146
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 17, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Patent number: 10507242
    Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: December 17, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Jay Harper, Scott Lonning, Frank Hsu
  • Patent number: 10494439
    Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: December 3, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
  • Patent number: 10464962
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 5, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 10457664
    Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R? represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3 (wherein R3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3 (wherein R3 is as defined hereinbefore); 3) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: October 29, 2019
    Assignee: Genzyme Corporation
    Inventors: Andrew Peter Thomas, Elaine Sophie Elizabeth Stokes, Laurent Francois Andre Hennequin
  • Patent number: 10450563
    Abstract: Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: October 22, 2019
    Assignee: Genzyme Corporation
    Inventors: Lisa M. Stanek, Adam Palermo, Brenda Richards, Sergio Pablo Sardi, Catherine O'Riordan, Antonius Song
  • Patent number: 10429288
    Abstract: Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: October 1, 2019
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, Brenda Burnham
  • Patent number: 10421949
    Abstract: Provided herein are methods of culturing an adherent mammalian cell in a shake tube using a plurality of microcarriers and batch re-feed perfusion, and various methods that utilize these culturing methods.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: September 24, 2019
    Assignee: Genzyme Corporation
    Inventors: Jianguo Yang, Yang Yang
  • Publication number: 20190263782
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: May 8, 2019
    Publication date: August 29, 2019
    Applicant: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Patent number: 10385108
    Abstract: Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (?-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the ?-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 20, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Michael A. Perricone, John Lyle Dzuris, Timothy E. Weeden, James E. Stefano, Clark Q. Pan, Andrea E. Edling
  • Patent number: 10383953
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: August 20, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Matthew Adamowicz
  • Patent number: 10377819
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 13, 2019
    Assignees: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath